Related Experiment Video
Updated: Sep 26, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
New Digital Health Technologies for Insulin Initiation and Optimization for People With Type 2 Diabetes
David Kerr1, Steven Edelman2, Giacomo Vespasiani3
1Sansum Diabetes Research Institute, Santa Barbara, California.
Summary
New digital health technologies can help overcome barriers to insulin therapy for type 2 diabetes. These tools improve glycemic control and reduce treatment burden, leading to better patient outcomes.
Area of Science:
- Endocrinology
- Digital Health
- Diabetes Management
Background:
- Type 2 diabetes poses a significant global health and economic challenge.
- Insulin therapy is crucial for managing complications but faces initiation and optimization barriers.
- Sustained hyperglycemia results from these barriers, impacting patient health.
Purpose of the Study:
- To review new and emerging technologies for insulin therapy.
- To identify opportunities to overcome barriers in insulin initiation and optimization.
- To assess the potential of digital health tools in diabetes management.
Main Methods:
- Focused literature search of PubMed and scientific congresses.
- Manual filtering of over 300 publications and abstracts.
- Identification of software tools and devices for insulin support.
Main Results:
- Most software tools are smartphone-based, showing comparable or improved glycemic outcomes.
- Benefits include reduced time burden and enhanced provider knowledge.
- New devices primarily assist with insulin dose and timing tracking, but evidence quality is limited.
Conclusions:
- Digital health tools show promise in reducing barriers to optimal insulin therapy.
- Integrated solutions connecting glucose monitoring, dosing, and lifestyle factors can simplify treatment.
- Improved adherence and outcomes are anticipated with comprehensive digital health integration.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
424
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
424
01:16Insulin: Dosing Regimen and Adverse Effects
285
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
285
01:22Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
01:27Insulin Formulations: Types and Delivery
287
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
287
01:22Diabetes Mellitus: Overview and Type I Subtype
3.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.4K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
319
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
319